In September, the Eurasian Community for Access to Treatment (ECAT) sent a letter to Otsuka calling for urgent action to expand access to delamanid — a critical drug for people with multidrug-resistant and rifampicin-resistant TB. One of the main demands is to reduce the price of a six-month course of delamanid to under US$300. Procurement monitoring data shows that in 2025, purchasing prices in the Eastern Europe and Central Asia (EECA) region imposed a heavy burden on national budgets, ranging from approximately US$1,190 to US$2,196 per course. Beyond pricing, ECAT highlighted key patent and licensing barriers — demanding an end to patent enforcement blocking generic supply and an expansion of licensing agreements to all EECA countries.
Read more here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #27, 12 October 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : TB CAB
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.